NUS Medicine and 22Health Ventures announce joint healthtech accelerator

Bridging the gap between clinical innovation and commercial success—Singapore’s leading medical school partners with healthcare investors to accelerate digital health ventures

The Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and 22Health Ventures announced the establishment of the NUS Medicine Digital Advanced Technology Accelerator (DATA)—a strategic partnership combining academic medical excellence with healthcare investment expertise to transform promising digital health concepts into commercially viable ventures.

Strategic Partnership Model

The collaboration addresses a fundamental challenge in healthcare innovation: exceptional clinical ideas often fail to achieve market impact due to gaps in business development, regulatory navigation, and investor connections. By uniting NUS Medicine’s clinical credibility with 22Health Ventures’ investment networks and commercialisation expertise, DATA provides comprehensive support that spans the entire journey from concept validation to market readiness.

NUS Medicine contributes Singapore’s leading medical school resources—clinical expertise for product validation, healthcare system access for real-world testing, and academic rigour ensuring solutions meet clinical standards.

22Health Ventures brings early-stage healthtech investment experience across Asia Pacific—investment frameworks, healthcare industry networks, and commercialisation strategies essential for scaling beyond pilot programmes.

Accelerator Programme Framework

DATA provides structured support addressing the multidimensional challenges healthcare startups face: clinical validation pathways connecting founders with healthcare providers, business model development ensuring commercial viability alongside clinical impact, healthcare market access strategies for regional and global expansion, mentorship from healthcare professionals and investment experts, and ecosystem connections to investors and strategic partners.

Building Singapore’s HealthTech Leadership

The partnership strengthens Singapore’s position as Southeast Asia’s healthcare innovation hub—combining world-class medical institutions, supportive regulatory environments, and strategic geographic positioning. By providing early-stage ventures with the clinical validation, business development, and investor access typically unavailable until later stages, DATA accelerates the path from innovation to implementation.

The accelerator represents a new model for healthcare innovation support—one that recognises successful healthcare ventures require both clinical excellence and commercial sophistication.